MABs Flashcards
Adalimumab
Anti-TNF
Rheumatoid arthritis
Psoriatic arthritis
Ankylosing spondylitis
Afatinib
TK inhibitor - EGFR, ERBB2, ERBB4
NSCLC (EGFR mutation +ve excluding T790M)
Alemtuzumab
Anti-CD52 (Humanised IgG1)
CML
Anakinra
IL1 blockade
Rheumatoid arthritis
Axitinib
TK inhibitor - VEGFR1/2/3, PDGFRb, c-KIT
RCC (2nd line)
Basiliximab
Anti-IL2R
Transplant
Anti-CD25
Belatacept
T cell co-stimulation blocker (Fc protein + CTLA4)
Transplant
Belimumab
Anti-BLYs/BAFF
Inhibits B cell proliferation/survival
SLE
Benralizumab
Anti-IL5 R alpha
Asthma
Bevacizumab
Bevacizumab is a recombinant, humanized monoclonal antibody.
Neturalizes VEGF, preventing its association with endothelial receptors, Flt-1 and KDR
CRC
Ovarian cancer
CNS cancer
Bezlotoxumab
Anti-C.diff toxin B
C.diff recurrent infection
Blinatumomab
Bi-specific T-cell engaging antibody
Acute lymphoblastic leukaemia (relapsed disease)
Bortezomib
Proteasome inhibitor
-Inhibit NF-kappa B
Multiple myeloma
Brentuximab
Anti-CD30 conjugated antibody
Hodgkin’s Disease
Brodalumab
Anti-17R
Psoriasis
Canakinumab
Anti-IL1b
Rheumatoid arthritis
Autoinflammatory disease
Certolizumab pegol
Anti-TNF
Crohn’s
Cetuximab
EGFR inhibitor
Head and neck SCC
Metastatic CRC
Must be KRAS Wild Type!
Criznlizumab
P-selectin glycoprotein ligand 1
Sickle cell crisis
Crizotinib
TK inhibitor - ALK and Ros1 inhibitor
NSCLC
Dabrafenib
TK inhibitor - BRAF
Melanoma (BRAF V600)
Daclizumab
Anti-IL2R
Renal transplant
Dasatinib
TK inhibitor
Bcr-Abl, SRC, c-kit, ephrin receptors
CML
Denosumab
Denosumab binds to RANKL, blocks the interaction between RANKL and RANK (a receptor located on osteoclast surfaces), and prevents osteoclast formation, leading to decreased bone resorption and increased bone mass in osteoporosis.
Eculizumab
Anti-C5
PNH
aHUS
Efalizumab
Anti-CD11a
Psoriasis
Eltrombopag
Eltrombopag is a thrombopoietin (TPO) nonpeptide agonist which increases platelet counts by binding to and activating the human TPO receptor. Activates intracellular signal transduction pathways to increase proliferation and differentiation of marrow progenitor cells.
ITP
Erlotinib
TK inhibitor - EGFR receptor
NSCLC (EGFR Mutation +ve, excluding T790M)
Evolocumab
PCSK9 inhibitor
Familial hypercholesterolaemia
Etanercept
TNF blockade
RA
PsA
Ank Spon
Gefitinib
TK inhibitor - EGFR
NSCLC (EGFR mutation +ve, excluding T790M)
Golimumab
Anti-TNF
RA
PsA
Ank Spon
Ibritumomab tiuxetan
Anti-CD20
NHL
Ibrutinib
BTK inhibitor (B cells)
CLL Waldenstrom's Mantle cell lymphoma Marginal zone lymphoma Chronic GVHD
Idarucizumab
Dabigatran reversal
Imatinib
TK Inhibitor - BCR-ABL pathway
CML (Ph+)
GIST
ALL (Ph+)
Infliximab
Anti-TNF
Crohn’s disease
Ipilimumab
Anti-CTLA4
Metastatic melanoma
Ixekizumab
Anti-IL17a
Psoriasis
Lapatinib
TK inhibitor - HER2
HER2+ Breast cancer (2nd line)
Mepolizumab
Anti-IL5
Asthma
Mongersen
SMAD7 Antisense olignucleotide
Crohn’s
Nataolizumab
Anti-a4 integrin
Multiple sclerosis
Nilotinib
TK Inhibitor - Bcr-Abl kinase
CML
GIST - off label
Nintedanib
TKI - BEGFR, FGFR
Idiopathic pulmonary fibrosis
Nivolumab
Anti-PD1
Melanoma
Obinutuzumab
Anti-CD20
CLL
Ofatumumab
Anti-CD20
CLL
Omalizumab
Anti-IgE
Asthma
Olaparib
TK inhibitor - PARP
BRCA mutated high-grade serious epithelial ovarian ca
Fallopian tube
Primary peritoneal ca
Osimmertinib
EGFR TKI
NSCLC T790M mutation EGFR gene
Palibociclib
CDK4/6 inhibitor
ER+ Breast Ca
Panitumumab
Anti-EGFR
CRC
Pazopanib
BEGFR1/2/3, PDGFR, KIT
RCC
Sarcoma
Pembrolizumab
Anti-PD1
Melanoma
Pembrolizumab is a highly selective anti-PD-1 humanized monoclonal antibody which inhibits programmed cell death-1 (PD-1) activity by binding to the PD-1 receptor on T-cells to block PD-1 ligands (PD-L1 and PD-L2) from binding.
Peruzumab
Anti-HER2/HER3
Extracellular dimerization domain of HER2
Ponatinib
BCR-ABL1 TKI
Quizartinib
FLT-3 inhibitor
Ramucirumab
Anti-VEGF receptor
Gastric ca
Reslizumab
Anti-CD20
NHL
Romosozumab
Sclerostin inhibitor
Osteoporosis
Ruxolitinib
Jak1/2/ inhibitor
Myeloproliferation
Secukinumab
Anti-IL17a
Psoriasis
Siltuximab
Anti-IL 6
Castleman disease
Sorafenib
TK inhibitor - BEGFR2/3, PDGFR, C-Raf> B-raf, KIT
Advanced RCC
Unresectable HCC
Thyroid ca
Sunitinib
TK inhibitor - FGF, PDGFR, RET, FLT3, VEGFR1/2 receptors, CD 117 (c-KIT) inhibitor
GIST
RCC
Pancreatic neuroendocrine tumours
Tocilizumab
Anti-IL6R (Humanised IgG1)
RA
GCA
Tofacitinib
Jak3 inhibitor
RA
Tositumomab
Anti-CD20
NHL
Trastuzumab
Anti-HER2 (extracellular)
Metastatic breast ca (HER2+)
GI cancer
Ustekinumab
Anti-IL12/23
Psoriasis
Vedolizumab
Anti-a4b7 integrin
UC
CD
Vemurafenib
TK inhibitor - B-Raf inhibitor
Melanoma (BRAF V600 mutation)
Dupilumab
Anti- IL4, IL 13
Asthma, moderate to severe eosinophilic or oral glucocorticoid dependent
Atopic dermatitis
Rhinosinusitis (chronic) with nasal polyposis